CN102863428B - 作为丙型肝炎病毒抑制剂的螺环化合物 - Google Patents
作为丙型肝炎病毒抑制剂的螺环化合物 Download PDFInfo
- Publication number
- CN102863428B CN102863428B CN201210239748.8A CN201210239748A CN102863428B CN 102863428 B CN102863428 B CN 102863428B CN 201210239748 A CN201210239748 A CN 201210239748A CN 102863428 B CN102863428 B CN 102863428B
- Authority
- CN
- China
- Prior art keywords
- independently
- compound
- alkyl
- radical
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC*(*)=C(CCI=C)Nc(*1c2NC(C)C(*)(CCC(*)C*)*1)ccc2NC1*(*)C*C1 Chemical compound CC*(*)=C(CCI=C)Nc(*1c2NC(C)C(*)(CCC(*)C*)*1)ccc2NC1*(*)C*C1 0.000 description 23
- TZGQDLUKXXHZLM-UHFFFAOYSA-N C(C1)CNC1c1ncc(-c(cc2)ccc2-c(c(C2)c3CC22CCCCC2)ccc3-c2cnc(C3NCCC3)[nH]2)[nH]1 Chemical compound C(C1)CNC1c1ncc(-c(cc2)ccc2-c(c(C2)c3CC22CCCCC2)ccc3-c2cnc(C3NCCC3)[nH]2)[nH]1 TZGQDLUKXXHZLM-UHFFFAOYSA-N 0.000 description 1
- BKQXDGIRKKLXPD-FCUFFLNPSA-N CC(C)C(C(N(CCC1)[C@@H]1c1ncc(-c(cc2)ccc2-c(cc2)c(CC3(CCCC3)C3)c3c2-c(cc2)nc3c2nc([C@H](CCC2)N2C([C@H](C(C)C)NC(OC)=O)=O)[nH]3)[nH]1)=O)NC(OC)=O Chemical compound CC(C)C(C(N(CCC1)[C@@H]1c1ncc(-c(cc2)ccc2-c(cc2)c(CC3(CCCC3)C3)c3c2-c(cc2)nc3c2nc([C@H](CCC2)N2C([C@H](C(C)C)NC(OC)=O)=O)[nH]3)[nH]1)=O)NC(OC)=O BKQXDGIRKKLXPD-FCUFFLNPSA-N 0.000 description 1
- LNLSIXKNYQWOSP-UHFFFAOYSA-N CC(C)C(C(N1CCCC1)=O)NC(OC)=O Chemical compound CC(C)C(C(N1CCCC1)=O)NC(OC)=O LNLSIXKNYQWOSP-UHFFFAOYSA-N 0.000 description 1
- ZZTQFDYTFSLDIW-SWEGCAAESA-N CC(C)[C@@H](C(N(CCC1)[C@@H]1c1nc(ccc(-c(cc2)c(CC3(CCCC3)C3)c3c2-c2ccc(-c3cnc(C(CCC4)N4C([C@H](C(C)C)NC(OC)=O)=O)[nH]3)[s]2)c2)c2[nH]1)=O)NC(O)OC Chemical compound CC(C)[C@@H](C(N(CCC1)[C@@H]1c1nc(ccc(-c(cc2)c(CC3(CCCC3)C3)c3c2-c2ccc(-c3cnc(C(CCC4)N4C([C@H](C(C)C)NC(OC)=O)=O)[nH]3)[s]2)c2)c2[nH]1)=O)NC(O)OC ZZTQFDYTFSLDIW-SWEGCAAESA-N 0.000 description 1
- GAEXLMLKMSWIHP-SXWICGLRSA-N CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)ccc2-c(c2c3CC4(CCCC4)C2)ccc3-c2cnc(C(CCC3)N3C([C@H](C(C)C)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)ccc2-c(c2c3CC4(CCCC4)C2)ccc3-c2cnc(C(CCC3)N3C([C@H](C(C)C)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O GAEXLMLKMSWIHP-SXWICGLRSA-N 0.000 description 1
- UMBLZBRILIAXJS-QXSHOWHUSA-N CC(C)[C@@H](C(N(C[C@@H](C1)F)[C@@H]1C(OCC(c(cc1)ccc1-c(cc1)c(CC2(CCCC2)C2)c2c1C(COC(C(C[C@H](C1)F)N1C([C@H](C(C)C)NC(OC)=O)=O)=O)=O)=O)=O)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)F)[C@@H]1C(OCC(c(cc1)ccc1-c(cc1)c(CC2(CCCC2)C2)c2c1C(COC(C(C[C@H](C1)F)N1C([C@H](C(C)C)NC(OC)=O)=O)=O)=O)=O)=O)=O)NC(OC)=O UMBLZBRILIAXJS-QXSHOWHUSA-N 0.000 description 1
- UBVLNROZKCSHAX-HRDYMLBCSA-N CC(C)[C@H](C(N(C[C@@H](C1)F)[C@@H]1C(O)=O)=O)NC(OC)=O Chemical compound CC(C)[C@H](C(N(C[C@@H](C1)F)[C@@H]1C(O)=O)=O)NC(OC)=O UBVLNROZKCSHAX-HRDYMLBCSA-N 0.000 description 1
- BEVCCTNFEGQILN-UHFFFAOYSA-N CC(CC1)CCC1(Cc1c(C)ccc(C)c11)C1=O Chemical compound CC(CC1)CCC1(Cc1c(C)ccc(C)c11)C1=O BEVCCTNFEGQILN-UHFFFAOYSA-N 0.000 description 1
- BSRPVFPQWOQTIW-UHFFFAOYSA-N CN(CCC1)C1I Chemical compound CN(CCC1)C1I BSRPVFPQWOQTIW-UHFFFAOYSA-N 0.000 description 1
- NCPLSOPWOCTMOU-UHFFFAOYSA-N Cc1nc(CCOc2c-3ccc(C)c2)c-3[nH]1 Chemical compound Cc1nc(CCOc2c-3ccc(C)c2)c-3[nH]1 NCPLSOPWOCTMOU-UHFFFAOYSA-N 0.000 description 1
- FAGLOQMYSBDWGF-UHFFFAOYSA-N O=C(CBr)c(cc1)ccc1-c(cc1)c(CC2(C3)CCCCC2)c3c1C(CBr)=O Chemical compound O=C(CBr)c(cc1)ccc1-c(cc1)c(CC2(C3)CCCCC2)c3c1C(CBr)=O FAGLOQMYSBDWGF-UHFFFAOYSA-N 0.000 description 1
- GIIDWCACMFAQJR-UHFFFAOYSA-N O=C(CBr)c(cc1)ccc1-c(cc1)c(CC2(CCCC2)C2)c2c1C(CBr)=O Chemical compound O=C(CBr)c(cc1)ccc1-c(cc1)c(CC2(CCCC2)C2)c2c1C(CBr)=O GIIDWCACMFAQJR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210239748.8A CN102863428B (zh) | 2011-07-09 | 2012-07-09 | 作为丙型肝炎病毒抑制剂的螺环化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110195113 | 2011-07-09 | ||
| CN201110195113.8 | 2011-07-09 | ||
| CN201210239748.8A CN102863428B (zh) | 2011-07-09 | 2012-07-09 | 作为丙型肝炎病毒抑制剂的螺环化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102863428A CN102863428A (zh) | 2013-01-09 |
| CN102863428B true CN102863428B (zh) | 2014-12-24 |
Family
ID=47442590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210239748.8A Active CN102863428B (zh) | 2011-07-09 | 2012-07-09 | 作为丙型肝炎病毒抑制剂的螺环化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9303061B2 (enExample) |
| EP (1) | EP2730572B1 (enExample) |
| JP (1) | JP2014520822A (enExample) |
| KR (1) | KR20140053166A (enExample) |
| CN (1) | CN102863428B (enExample) |
| AU (1) | AU2012283609B2 (enExample) |
| BR (1) | BR112014000563A2 (enExample) |
| CA (1) | CA2841095A1 (enExample) |
| TW (1) | TWI482766B (enExample) |
| WO (1) | WO2013007106A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| KR20140040801A (ko) | 2011-07-15 | 2014-04-03 | 시오노기세야쿠 가부시키가이샤 | Ａｍｐｋ 활성화 작용을 갖는 아자벤즈이미다졸 유도체 |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI610916B (zh) * | 2012-08-03 | 2018-01-11 | 廣東東陽光藥業有限公司 | 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用 |
| TW201412709A (zh) * | 2012-09-28 | 2014-04-01 | Sunshine Lake Pharma Co Ltd | 作為丙型肝炎抑制劑的螺環化合物及其在藥物中的應用 |
| US9416139B2 (en) * | 2012-11-29 | 2016-08-16 | Sunshine Lake Pharma Co., Ltd. | Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof |
| TW201439060A (zh) * | 2013-02-27 | 2014-10-16 | Sunshine Lake Pharma Co Ltd | 作爲丙型肝炎抑制劑的橋環化合物及其藥物組合物和用途 |
| US9334291B2 (en) * | 2013-06-06 | 2016-05-10 | AB Pharma Ltd. | Antiviral compounds highly effective as HCV-NS5A inhibitor |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2015009744A1 (en) | 2013-07-17 | 2015-01-22 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of hcv |
| WO2015110048A1 (en) | 2014-01-23 | 2015-07-30 | Sunshine Lake Pharma Co., Ltd. | Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof |
| CN104860931A (zh) * | 2014-02-21 | 2015-08-26 | 常州寅盛药业有限公司 | 丙肝病毒抑制剂及其制药用途 |
| CN105085493A (zh) * | 2014-04-15 | 2015-11-25 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的螺环化合物及其在药物中的应用 |
| WO2015184644A1 (zh) * | 2014-06-06 | 2015-12-10 | 爱博新药研发(上海)有限公司 | 抑制丙肝病毒的化合物、药物组合物及其应用 |
| JP2017529401A (ja) | 2014-09-26 | 2017-10-05 | チャーンジョウ インシュヨン ファーマシューティカル カンパニー，リミティド | Ｎｓ４ｂ阻害剤としてのベンゾフラン類似体 |
| WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| CN106432195B (zh) * | 2015-08-12 | 2020-01-14 | 杭州民生药物研究院有限公司 | 一种制备(r)-2-(2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺的方法 |
| CN105461701A (zh) * | 2015-12-14 | 2016-04-06 | 上海步越化工科技有限公司 | 一种抗丙肝新药达卡他韦新的合成方法 |
| CN105622583A (zh) * | 2015-12-22 | 2016-06-01 | 苏州步跃医药科技有限公司 | 一种抗丙肝新药达卡他韦新的制备方法 |
| CN112225778A (zh) * | 2020-10-26 | 2021-01-15 | 辰欣药业股份有限公司 | 一种马来酸依那普利的制备方法 |
| CN116120272A (zh) * | 2022-12-31 | 2023-05-16 | 淮北师范大学 | 一种合成咯菌腈中间体2,2-二氟-1,3-苯并二噁茂-4-甲醛的方法 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2999098A (en) * | 1957-11-13 | 1961-09-05 | Universal Oil Prod Co | Bis-halocycloalkenyl derivatives of alkylidenedioxybenzenes |
| FR2707982B1 (fr) * | 1993-07-20 | 1995-09-01 | Adir | Nouveaux dérivés de benzospiroalcène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8642660B2 (en) * | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| BRPI0922366B8 (pt) * | 2008-12-03 | 2021-05-25 | Presidio Pharmaceuticals Inc | composto, composição farmacêutica e uso de um composto |
| US8314135B2 (en) | 2009-02-09 | 2012-11-20 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole antivirals |
| US8426458B2 (en) | 2009-02-27 | 2013-04-23 | Enanta Pharmaceuticals, Inc. | Hepatitis C Virus inhibitors |
| EP2410843A4 (en) | 2009-03-27 | 2012-08-08 | Presidio Pharmaceuticals Inc | FUSIONED CORE INHIBITORS OF HEPATITIS C |
| KR101387274B1 (ko) * | 2009-03-27 | 2014-04-25 | 머크 샤프 앤드 돔 코포레이션 | Ｃ형 간염 바이러스 복제의 억제제 |
| EP2410841A4 (en) | 2009-03-27 | 2012-10-24 | Presidio Pharmaceuticals Inc | SUBSTITUTED BICYCLIC HCV INHIBITORS |
| US8796466B2 (en) * | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5734956B2 (ja) * | 2009-04-15 | 2015-06-17 | アッヴィ・インコーポレイテッド | 抗ウィルス化合物 |
| US20120115918A1 (en) | 2009-04-15 | 2012-05-10 | Abbott Laboratories | Anti-Viral Compounds |
| JP2012526834A (ja) | 2009-05-12 | 2012-11-01 | シェーリング コーポレイション | ウイルス疾患治療に有用な縮合型三環式アリール化合物 |
| MX363732B (es) | 2009-05-13 | 2019-04-01 | Gilead Pharmasset Llc Star | Compuestos antivirales. |
| SG176137A1 (en) | 2009-05-18 | 2011-12-29 | Actelion Pharmaceuticals Ltd | Bridged spiro [2.4] heptane derivatives as alx receptor and/or fprl2 agonists |
| AU2010253790A1 (en) | 2009-05-29 | 2011-12-15 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as Hepatitis C |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2011004276A1 (en) | 2009-07-06 | 2011-01-13 | Pfizer Limited | Hepatitis c virus inhibitors |
| JP2012533569A (ja) * | 2009-07-16 | 2012-12-27 | ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド | フラビウイルス感染症を治療又は予防するためのベンゾイミダゾール類似体 |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| EP2503881B1 (en) | 2009-11-25 | 2015-05-13 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| AR079528A1 (es) | 2009-12-18 | 2012-02-01 | Idenix Pharmaceuticals Inc | Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c |
| US20130156731A1 (en) | 2009-12-22 | 2013-06-20 | Kevin X. Chen | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas |
| CA2784036A1 (en) | 2009-12-24 | 2011-06-30 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| CA2794145A1 (en) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| AU2011232348A1 (en) | 2010-03-24 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of Flavivirus infections |
| US20110312996A1 (en) | 2010-05-17 | 2011-12-22 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| EP2575866A4 (en) | 2010-05-24 | 2013-10-16 | Presidio Pharmaceuticals Inc | HCV NS5A INHIBITORS |
| AR081848A1 (es) | 2010-06-09 | 2012-10-24 | Presidio Pharmaceuticals Inc | Inhibidores de la proteina ns5a del vhc |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| WO2012003642A1 (en) | 2010-07-09 | 2012-01-12 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and use thereof for treating viral diseases |
| US8815849B2 (en) | 2010-07-26 | 2014-08-26 | Janssen R&D Ireland | Hetero-bicyclic derivatives as HCV inhibitors |
| AU2011286276A1 (en) | 2010-07-26 | 2013-01-24 | Merck Sharp & Dohme Corp. | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2012020036A1 (en) | 2010-08-13 | 2012-02-16 | F. Hoffmann-La Roche Ag | Hepatitis c virus inhibitors |
| WO2012050918A2 (en) | 2010-09-29 | 2012-04-19 | Presidio Pharmaceutical, Inc. | Tricyclic fused ring inhibitors of hepatitis c |
| WO2012040924A1 (en) | 2010-09-29 | 2012-04-05 | Merck Sharp & Dohme Corp. | Fused tetracyclic heterocycle compounds and methods of use thereof for treatment of viral diseases |
| EP2621932A4 (en) | 2010-09-29 | 2014-03-26 | Merck Sharp & Dohme | TETRACYCLIC HETEROCYCLUS COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS |
| JP2013538831A (ja) | 2010-09-29 | 2013-10-17 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｃ型肝炎ウィルス感染治療のための四環式インドール誘導体 |
| WO2012040923A1 (en) | 2010-09-29 | 2012-04-05 | Merck Sharp & Dohme Corp. | Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases |
| CA2812779A1 (en) | 2010-09-29 | 2012-04-19 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
| PT3042910T (pt) * | 2010-11-30 | 2019-04-16 | Gilead Pharmasset Llc | 2'-espiro-nucleósidos para utilização na terapia da hepatite c |
| WO2012083048A2 (en) | 2010-12-15 | 2012-06-21 | Abbott Laboratories | Anti-viral compounds |
| EP2651926A4 (en) | 2010-12-15 | 2014-07-09 | Abbvie Inc | ANTI-VIRAL COMPOUNDS |
| WO2012122716A1 (en) | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases |
| WO2013022810A1 (en) | 2011-08-08 | 2013-02-14 | Glaxosmithkline Llc | Chemical compounds |
| WO2013021337A1 (en) | 2011-08-08 | 2013-02-14 | Lupin Limited | Antiviral compounds with a fused tricyclic ring |
| PT3431477T (pt) | 2011-11-16 | 2020-12-15 | Gilead Pharmasset Llc | Imidazolilimidazolos condensados como compostos antivirais |
| CN104203940B (zh) | 2011-12-28 | 2017-01-18 | 爱尔兰詹森科学公司 | 作为hcv抑制剂的杂双环衍生物 |
| AU2013217224B2 (en) | 2012-02-10 | 2017-04-06 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
-
2012
- 2012-07-09 EP EP12811420.4A patent/EP2730572B1/en not_active Not-in-force
- 2012-07-09 WO PCT/CN2012/000945 patent/WO2013007106A1/zh not_active Ceased
- 2012-07-09 CA CA2841095A patent/CA2841095A1/en not_active Abandoned
- 2012-07-09 CN CN201210239748.8A patent/CN102863428B/zh active Active
- 2012-07-09 KR KR1020147002974A patent/KR20140053166A/ko not_active Withdrawn
- 2012-07-09 BR BR112014000563-0A patent/BR112014000563A2/pt not_active Application Discontinuation
- 2012-07-09 JP JP2014519378A patent/JP2014520822A/ja active Pending
- 2012-07-09 TW TW101124685A patent/TWI482766B/zh not_active IP Right Cessation
- 2012-07-09 US US14/130,320 patent/US9303061B2/en not_active Expired - Fee Related
- 2012-07-09 AU AU2012283609A patent/AU2012283609B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN102863428A (zh) | 2013-01-09 |
| US20140147412A1 (en) | 2014-05-29 |
| US9303061B2 (en) | 2016-04-05 |
| TWI482766B (zh) | 2015-05-01 |
| BR112014000563A2 (pt) | 2019-12-10 |
| AU2012283609B2 (en) | 2016-09-29 |
| HK1191935A1 (en) | 2014-08-08 |
| TW201302731A (zh) | 2013-01-16 |
| EP2730572A4 (en) | 2014-12-10 |
| EP2730572B1 (en) | 2015-09-16 |
| EP2730572A1 (en) | 2014-05-14 |
| WO2013007106A1 (zh) | 2013-01-17 |
| AU2012283609A1 (en) | 2014-02-20 |
| CA2841095A1 (en) | 2013-01-17 |
| KR20140053166A (ko) | 2014-05-07 |
| JP2014520822A (ja) | 2014-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102863428B (zh) | 作为丙型肝炎病毒抑制剂的螺环化合物 | |
| CN103570693B (zh) | 作为丙型肝炎抑制剂的桥环化合物及其在药物中的应用 | |
| CN103848821B (zh) | 作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们的用途 | |
| CN102459250B (zh) | 丙型肝炎病毒抑制剂 | |
| TWI616448B (zh) | 黃病毒科病毒之巨環狀抑制劑 | |
| CN103420991A (zh) | 作为丙型肝炎抑制剂的吡咯烷衍生物及其在药物中的应用 | |
| CN103709151B (zh) | 作为丙型肝炎抑制剂的螺环化合物及其在药物中的应用 | |
| CN104003980B (zh) | 作为丙型肝炎抑制剂的桥环化合物及其药物组合物和用途 | |
| CN103848819B (zh) | 作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们在药物中的应用 | |
| CN103880823B (zh) | 作为丙型肝炎抑制剂的螺环化合物及其在药物中的应用 | |
| CN103848820A (zh) | 作为丙型肝炎抑制剂的螺环化合物及其在药物中的应用 | |
| CN105884779A (zh) | 作为丙型肝炎抑制剂的化合物及其在药物中的应用 | |
| TWI600653B (zh) | 作爲丙型肝炎抑制劑的並環化合物、藥物組合物及它們在藥物中的應用 | |
| CN105384792A (zh) | 作为丙型肝炎抑制剂的化合物及其在药物中的应用 | |
| HK1191935B (en) | Spiro compounds as hepatitis c virus inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20130109 Assignee: Ru Yuan Dongyang light pharmaceutcal corporation, Ltd Assignor: Dongyangguang Pharmaceutical Co., Ltd., Guangdong Contract record no.: 2015440000197 Denomination of invention: Spiro-compounds taken as hepatitis c virus (HCV) inhibitor Granted publication date: 20141224 License type: Exclusive License Record date: 20150604 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210408 Address after: No.38 Binjiang Road, Yidu City, Yichang City, Hubei Province Patentee after: YICHANG HEC CHANGJIANG PHARMACEUTICAL Co.,Ltd. Address before: 523000 Songshan Lake Science and Technology Industrial Park, Dongguan, Guangdong Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd. |
|
| TR01 | Transfer of patent right |